Business Context and Reporting Period
Company: Propanc Health Group Corporation (formerly Propanc PTY LTD)
Reporting Period: Quarterly period ended December 31, 2011 (Six months ended Dec 31, 2011)
Status: Development stage biopharmaceutical company focused on cancer treatments.
Operations: Based in Richmond, Victoria, Australia. The company has no products on the market and has not generated revenue from operations. It is in the preclinical stage of development.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2011 | Six Months Ended Dec 31, 2010 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5,782,033) | $(1,041,034) |
| Operating Expenses | $5,951,989 | $1,120,714 |
| Cash Flow from Operations | $(40,157) | $(1,221,638) |
| Cash Flow from Financing | $80,330 | $1,268,958 |
| Cash Balance (End of Period) | $39,728 | $44,674 |
| Total Assets | $4,872,856 | $10,814,158 (June 30, 2011) |
| Total Liabilities | $354,272 | $306,849 (June 30, 2011) |
| Accumulated Deficit | $(9,628,373) | $(3,846,340) (June 30, 2011) |
Material Changes vs. Prior Period
- Expense Surge: Operating expenses increased significantly to $5.95 million for the six months ended Dec 31, 2011, compared to $1.12 million in the prior year. This was primarily driven by a non-cash amortization charge of $5.64 million related to prepaid common stock issued for services.
- Net Loss Expansion: Net loss widened to $5.78 million from $1.04 million year-over-year, largely due to the aforementioned stock-based compensation amortization.
- Asset Reduction: Total assets decreased from $10.8 million (June 30, 2011) to $4.9 million (Dec 31, 2011), reflecting the amortization of the prepaid stock asset.
- Debt Activity: The company issued convertible debentures totaling $69,012 during the period. Related party advances were reclassified to equity.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that conditions raise substantial doubt about the company's ability to continue as a going concern. The company has no revenue and an accumulated deficit of $9.6 million.
- Liquidity: Cash on hand ($39,728) is estimated to fund operations only until March 2012. The company estimates it requires approximately $7.5 million to fund operations and development for the next 12-18 months.
- Capital Needs: Management is actively seeking additional financing through the sale of registered securities. Failure to secure funds may force the company to delay or cease operations.
- Internal Controls: Management identified a material weakness in internal controls due to insufficient segregation of duties caused by small staff size.
- R&D Status: The company is undertaking preclinical activities for its lead product and has filed an international PCT patent application.
Investor Verification Checklist
- Capital Raise Status: Verify if the company has secured the estimated $7.5 million needed to survive beyond March 2012.
- Stock-Based Compensation: Review the valuation and amortization schedule of the $10.8 million prepaid stock issued for services, which drives the majority of current expenses.
- Related Party Transactions: Confirm the terms and repayment status of loans and advances from directors and related parties ($139,050 total owed).
- Patent Progress: Monitor the status of the international PCT patent application (No. PCT/AU2010/001403) and preclinical trial results.
- Internal Control Remediation: Assess if the company has hired additional accounting personnel to address the material weakness in financial reporting controls.